FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> China | R&D spending | India

U.S., Europe still lead in global R&D efforts

Booz & Co. has crunched the numbers on the 1,000 largest public R&D spenders and concluded that the U.S. still is way out in front among all the countries of the world for research. But the analysis also notes that while India and China are still relatively small players on the R&D front, they're growing fast. And 22 cents out of every R&D buck is being used for research related to health.

Of that money, "about 30 percent of R&D spend is devoted to research, and 70 percent to product development. And for the latter, about two-thirds is spent in emerging markets in order to recruit clinical trial participants cost-effectively. The research side has been slower to establish a presence in emerging markets; in 2007 close to 95 percent of R&D went to drug discovery in the U.S., Europe and Japan."

- check out the press release

Related Articles:
California initiative triggers research spending boom
Group: EU should double research spending
India's biopharma surges on outsourcing boom
India moves to back up emerging biotech industry
Pharma's new favorite outsourcing spot: China


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Research Email Newsletter:
Be the first to comment
More stories about India   China   R&D spending  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.